, targeting a market where patents for the original drug are set to expire in 2029 and 2031. The clinical trial, known under the identifier NCT06952478 , was designed to test CT-P44 as a subcutaneous (SC) injection in combination with other therapies over a two-year period. The Patient at the Center Imagine a patient in a relapsed state, someone for whom traditional therapies have failed. For them, CT-P44 represents more than just a "biosimilar candidate." It is a promise of
The drug is specifically formulated for , utilizing recombinant human hyaluronidase (rHuPH20) to allow for faster delivery under the skin. This delivery method is a biosimilar to Darzalex Faspro , which significantly reduces the administration time compared to traditional intravenous (IV) versions of the drug, which can take several hours. Clinical Development Status ct-p44